Research Library › GHRH & Ghrelin-Receptor
Hexarelin is a synthetic hexapeptide in the growth hormone-releasing peptide (GHRP) family, a close relative of GHRP-6, designed to act at the growth hormone secretagogue (ghrelin) receptor. It followed from the GHRP research line begun by Cyril Bowers at Tulane University in 1984, and was later studied at a second receptor, CD36, in cardiac research. As of 22 Oct 2026 hexarelin is not FDA-approved and has no identified approval elsewhere.
Key facts
| Type | Synthetic 6-amino-acid peptide (hexapeptide) |
|---|---|
| Derived from | GHRP-6, part of the synthetic GHRP family |
| First described | Follow-on to GHRP-6 (1984); exact year not confirmed in our sources |
| Developed by | GHRP research line originating with Cyril Y. Bowers, Tulane University |
| Designed target | Growth hormone secretagogue (ghrelin) receptor; also studied at CD36 |
| Regulatory status (Oct 2026) | Not FDA-approved; no approval identified elsewhere; named on WADA 2026 list (S2) |
Who developed it
Hexarelin belongs to the family of growth hormone-releasing peptides whose history begins with Cyril Y. Bowers at Tulane University Medical School in New Orleans. In 1984 Bowers and colleagues, including Frank Momany, reported GHRP-6. Hexarelin and GHRP-2 followed as six-amino-acid relatives built on the same template [1][2].
The name follows the convention of growth hormone-releasing compounds ending in “-relin,” as with sermorelin and tesamorelin, with the “hexa-” prefix pointing to its six amino acids. Of the GHRPs, it is the one most associated with research beyond the pituitary [2].
What it was designed to target
The GHRP family started from synthetic analogs of enkephalin, a natural opioid peptide, after Bowers observed that some of them caused pituitary cells to release growth hormone [2]. These peptides incorporate D-amino acids, the mirror-image form, and have no natural counterpart; Bowers called them “of unnatural origin” [1][2].
Hexarelin is designed to bind the growth hormone secretagogue receptor (GHS-R) on the pituitary. That receptor’s natural ligand, ghrelin, was not identified until 1999, when a team led by Masayasu Kojima and Kenji Kangawa purified it from the stomach [3].
Hexarelin also stands out within the family because researchers later reported that it interacts with a second receptor, CD36, a scavenger receptor found on heart and other tissues. That finding drew it into cardiac research [2].
Why it was created
The GHRPs offered a way to engage growth hormone release through a route separate from GHRH. Bowers regarded them as tools for investigating and testing growth hormone regulation, and as evidence of an unknown natural hormone [1]. Hexarelin was later investigated in small human studies in a research program on heart failure, while comparable GHRP-6 cardiac work stayed mostly in animal models [2].
Research timeline
- 1984: Bowers’ team at Tulane reports GHRP-6, the parent of the family [2].
- 1998: Bowers predicts a natural hypothalamic hormone acting through the GHRP receptor [1].
- 1999: Ghrelin is identified in the stomach as that receptor’s natural ligand [3].
- 2017: A historical review summarizes hexarelin’s cardiac research and its CD36 interaction [2].
Regulatory status as of October 2026
As of 22 Oct 2026, hexarelin is not FDA-approved, and we have not identified an approval in any other country. Within the GHRP family, only GHRP-2 has reached approval anywhere, as a diagnostic agent in Japan under the name pralmorelin [4]. FDA’s 2023 Category 2 compounding actions named GHRP-2 and GHRP-6 [5].
Hexarelin is covered by the 2026 World Anti-Doping Agency Prohibited List under S2 as a growth hormone-releasing peptide, prohibited at all times [6].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed hexarelin?
Hexarelin is a member of the growth hormone-releasing peptide family that began with Cyril Bowers’ work at Tulane University, where GHRP-6 was reported in 1984.
Is hexarelin FDA approved?
No. As of 22 Oct 2026 hexarelin is not FDA-approved, and no approval elsewhere has been identified. Within its peptide family, only GHRP-2 has been approved anywhere, as a diagnostic in Japan.
What receptors does hexarelin target?
It is designed to bind the growth hormone secretagogue (ghrelin) receptor. Researchers have also reported that it interacts with CD36, a scavenger receptor studied in cardiac research.
How is hexarelin related to GHRP-6?
Hexarelin is a six-amino-acid relative of GHRP-6 from the same family of synthetic growth hormone-releasing peptides.
Sources
- Bowers CY (Tulane University Medical School, New Orleans). Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316–1329. doi:10.1007/s000180050257. Link
- Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. doi:10.1177/1179546817694558. Link
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999 Dec 9;402:656–660. doi:10.1038/45230. Link
- KEGG DRUG. D02040 Pralmorelin hydrochloride (JAN); product GHRP (Kaken Pharmaceutical), Japan; efficacy: diagnostic; listed under new drug approvals in Japan. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List, S2.2.4 (GHRH and its analogues; growth hormone secretagogues; GH-releasing peptides). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
